[go: up one dir, main page]

WO2001064650A3 - Synthese d'epothilones, de leurs produits intermediaires et de leurs analogues - Google Patents

Synthese d'epothilones, de leurs produits intermediaires et de leurs analogues Download PDF

Info

Publication number
WO2001064650A3
WO2001064650A3 PCT/US2001/006643 US0106643W WO0164650A3 WO 2001064650 A3 WO2001064650 A3 WO 2001064650A3 US 0106643 W US0106643 W US 0106643W WO 0164650 A3 WO0164650 A3 WO 0164650A3
Authority
WO
WIPO (PCT)
Prior art keywords
analogues
epothilones
intermediates
synthesis
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/006643
Other languages
English (en)
Other versions
WO2001064650A2 (fr
Inventor
Samuel J Danishefsky
Chul Bom Lee
Mark Chappell
Shawn Stachel
Ting-Chao Chou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Priority to AU2001243372A priority Critical patent/AU2001243372A1/en
Priority to JP2001563492A priority patent/JP2004500388A/ja
Priority to EP01916335A priority patent/EP1259490A2/fr
Priority to CA002401800A priority patent/CA2401800A1/fr
Publication of WO2001064650A2 publication Critical patent/WO2001064650A2/fr
Publication of WO2001064650A3 publication Critical patent/WO2001064650A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La présente invention concerne des procédés convergents permettant de préparer des épothilones, des désoxyépothilones et leurs analogues. La présente invention concerne également de nouvelles compositions et de nouveaux procédés pour le traitement du cancer, ainsi que des procédés pour le traitement de cancers développant un phénotype de multirésistance médicamenteuse.
PCT/US2001/006643 2000-03-01 2001-03-01 Synthese d'epothilones, de leurs produits intermediaires et de leurs analogues Ceased WO2001064650A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001243372A AU2001243372A1 (en) 2000-03-01 2001-03-01 Synthesis of epothilones, intermediates thereto and analogues thereof
JP2001563492A JP2004500388A (ja) 2000-03-01 2001-03-01 エポチロン、その中間体およびその類似体の合成
EP01916335A EP1259490A2 (fr) 2000-03-01 2001-03-01 Synthese d'epothilones, de leurs produits intermediaires et de leurs analogues
CA002401800A CA2401800A1 (fr) 2000-03-01 2001-03-01 Synthese d'epothilones, de leurs produits intermediaires et de leurs analogues

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18596800P 2000-03-01 2000-03-01
US60/185,968 2000-03-01
US25044700P 2000-11-30 2000-11-30
US60/250,447 2000-11-30

Publications (2)

Publication Number Publication Date
WO2001064650A2 WO2001064650A2 (fr) 2001-09-07
WO2001064650A3 true WO2001064650A3 (fr) 2002-05-10

Family

ID=26881647

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/006643 Ceased WO2001064650A2 (fr) 2000-03-01 2001-03-01 Synthese d'epothilones, de leurs produits intermediaires et de leurs analogues

Country Status (5)

Country Link
EP (1) EP1259490A2 (fr)
JP (1) JP2004500388A (fr)
AU (1) AU2001243372A1 (fr)
CA (1) CA2401800A1 (fr)
WO (1) WO2001064650A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849651B2 (en) 1996-12-03 2005-02-01 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6965034B2 (en) 1996-12-03 2005-11-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US8034815B2 (en) 2007-01-11 2011-10-11 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
US8895556B2 (en) 2007-12-26 2014-11-25 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US9284275B2 (en) 2007-01-11 2016-03-15 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2384789T3 (es) 2001-03-14 2012-07-12 Bristol-Myers Squibb Company Combinación de un análogo de epotilona y agentes quimioterapéuticos para el tratamiento de enfermedades proliferativas
EP1575556A2 (fr) * 2002-05-20 2005-09-21 Kosan Biosciences, Inc. Methodes d'administration d'epothilone d
RU2379032C9 (ru) * 2002-06-10 2010-03-27 Новартис Аг Комбинации, включающие эпотилоны, и их фармацевтическое применение
BR0311714A (pt) * 2002-06-10 2005-03-01 Novartis Ag Combinações que compreendem epotilonas e seus usos farmacêuticos
DK1521752T3 (da) * 2002-07-15 2009-06-22 Helmholtz Infektionsforschung Makrocykliske forbindelser til behandling af cancer
AR040956A1 (es) 2002-07-31 2005-04-27 Schering Ag Nuevos conjugados de efectores, procedimientos para su preparacion y su uso farmaceutico
KR20050026033A (ko) * 2002-07-31 2005-03-14 쉐링 악티엔게젤샤프트 신규 효과기 접합체, 그의 제조 방법 및 그의 약학적 용도
PT1767535E (pt) 2002-08-23 2010-02-24 Sloan Kettering Inst Cancer Síntese de epotilonas, respectivos intermediários, análogos e suas utilizações
US7384964B2 (en) * 2002-08-23 2008-06-10 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
CA2501610C (fr) * 2002-10-11 2012-01-03 Dana-Farber Cancer Institute Inc Derives epothilone pour le traitement du myelome multiple
JP2005095152A (ja) * 2003-08-29 2005-04-14 Japan Tissue Engineering:Kk 培養組織の保存方法
EP1674098A1 (fr) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Formulations parenterales stables et tolérables des substances de haut réactivité ayant une solubilité basse ou inexistante dans l'eau
EP2065054A1 (fr) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinaisons comprenant une prostaglandine et leurs utilisations
EP2070521A1 (fr) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Nanoparticules à surface modifiée
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2210584A1 (fr) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Composition polymère stable comprenant un copolymère séquencé d'épothilone et amphiphile
US9717803B2 (en) 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
WO2014009426A2 (fr) 2012-07-13 2014-01-16 Innate Pharma Criblage d'anticorps conjugués
US10036010B2 (en) 2012-11-09 2018-07-31 Innate Pharma Recognition tags for TGase-mediated conjugation
US9309259B2 (en) * 2013-03-08 2016-04-12 Scinopharm Taiwan, Ltd. Process for ixabepilone, and intermediates thereof
EP2968582B1 (fr) 2013-03-15 2020-07-01 Innate Pharma Conjugaison d'anticorps en phase solide médiée par la tgase
EP3010547B1 (fr) 2013-06-20 2021-04-21 Innate Pharma Conjugaison enzymatique de polypeptides
AU2014283185B2 (en) 2013-06-21 2019-05-02 Araris Biotech Ltd. Enzymatic conjugation of polypeptides
WO2019092148A1 (fr) 2017-11-10 2019-05-16 Innate Pharma Anticorps avec des résidus de glutamine fonctionnalisés
SG11202110436UA (en) * 2019-04-05 2021-10-28 Prolynx Llc Improved conjugation linkers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HARRIS C R ET AL: "COMPLEX TARGET-ORIENTED SYNTHESIS IN THE DRUG DISCOVERY PROCESS: A CASE HISTORY IN THE DEPOB SERIES", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 64, 1999, pages 8434 - 8456, XP000984318, ISSN: 0022-3263 *
NICOLAOU K C ET AL: "Chemical Biology of Epothilones", ANGEWANDTE CHEMIE. INTERNATIONAL EDITION, VERLAG CHEMIE. WEINHEIM, DE, vol. 37, no. 15, August 1998 (1998-08-01), pages 2014 - 2045, XP002131418, ISSN: 0570-0833 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849651B2 (en) 1996-12-03 2005-02-01 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6965034B2 (en) 1996-12-03 2005-11-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
USRE41990E1 (en) 1996-12-03 2010-12-07 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US8034815B2 (en) 2007-01-11 2011-10-11 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
US9284275B2 (en) 2007-01-11 2016-03-15 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
US8895556B2 (en) 2007-12-26 2014-11-25 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US9422282B2 (en) 2010-04-01 2016-08-23 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV

Also Published As

Publication number Publication date
CA2401800A1 (fr) 2001-09-07
JP2004500388A (ja) 2004-01-08
AU2001243372A1 (en) 2001-09-12
WO2001064650A2 (fr) 2001-09-07
EP1259490A2 (fr) 2002-11-27

Similar Documents

Publication Publication Date Title
WO2001064650A3 (fr) Synthese d'epothilones, de leurs produits intermediaires et de leurs analogues
EP1386922A3 (fr) Synthèse d'épitholones, intermédiaires, analogues et leur utilisation
IL138113A0 (en) Synthesis of epothilones, intermediates thereto and analogues thereof
IL157478A0 (en) Method for the synthesis of 2', 3'-didehydronucleosides
CA2475302A1 (fr) Synthese controlee de ziprasidone et ses compositions
WO2004037988A3 (fr) Methodes de synthese de l'adn complementaire
WO2004078757A3 (fr) Synthese
PL362715A1 (en) Process for the epoxidation of olefins
MXPA03008041A (es) Proceso para la fabricacion de articulos moldeados.
IL150432A0 (en) Process for the epoxidation of olefins
WO2003041653A3 (fr) Agents cytotoxiques
WO2004032908A3 (fr) Methode d'inhibition de l'angiogenese
EP1529777A3 (fr) Un procédé et un oxalidine comme intermédiare pour la synthèse des taxanes.
PL362616A1 (en) Process for the epoxidation of olefins
IT1317722B1 (it) Procedimento per la produzione di gas di sintesi.
WO2002047604A3 (fr) Utilisation des composes de la classe des chalcones pour inhiber la vascularisation d'une masse tumorale
MXPA02006102A (es) Metodo para preparar compuestos bormodifluoroaceticos.
AU2002330042A1 (en) Process for the preparation of 1,5-diarylpyrazoles
MXPA03002926A (es) Proceso para la sintesis de 2,2,6,6,-tetrametil-4--oxipiperidina.
AU2001277728A1 (en) Biphenylcarboxamidoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof
IL156331A0 (en) A process for the preparation of paclitaxel
WO2002096799A3 (fr) Sous-nitrure de silicium
MXPA02003042A (es) Proceso para prevenir formacion de incrustaciones.
AU4568301A (en) Process for adjusting the hardness of fischer-tropsch wax by blending
MXPA03009210A (es) PROCEDIMIENTO PARA LA PREPARACIoN DE OXABISPIDINAS.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2401800

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 563492

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001243372

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001916335

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001916335

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642